PURPOSE: To compare the effectiveness, tolerance, and pharmacokinetics of a single dose of pegfilgrastim to daily filgrastim in children and young adults with sarcomas treated with dose-intensive combination chemotherapy. EXPERIMENTAL DESIGN: Patients were randomized to receive a single dose of 100 mcg/kg of pegfilgrastim s.c. or 5 mcg/kg/day of filgrastim s.c., daily until neutrophil recovery after two treatment cycles with vincristine, doxorubicin, and cyclophosphamide (VDC) and two cycles of etoposide and ifosfamide (IE). The duration of severe neutropenia (absolute neutrophil count, < or =500/mcL) during cycles 1 to 4 and cycle duration for all cycles were compared. Pharmacokinetics of pegfilgrastim and filgrastim and CD34+ stem cell mobilization were studied on cycle 1. Growth factor-related toxicity, transfusions, and episodes of fever and neutropenia and infections were collected for cycles 1 to 4. RESULTS:Thirty-four patients (median age, 20 years; range 3.8-25.8) were enrolled, and 32 completed cycles 1 to 4. The median (range) duration of absolute neutrophil count of <500/mcL was 5.5 (3-8) days for pegfilgrastim and 6 (0-9) days for filgrastim (P = 0.76) after VDC, and 1.5 (0-4) days for pegfilgrastim and 3.75 (0-6.5) days for filgrastim (P = 0.11) after IE. More episodes of febrile neutropenia and documented infections occurred on the filgrastim arm. Serum pegfilgrastim concentrations were highly variable. Pegfilgrastim apparent clearance (11 mL/h/kg) was similar to that reported in adults. CONCLUSION: A single dose per cycle of pegfilgrastim was well tolerated and may be as effective as daily filgrastim based on the duration of severe neutropenia and number of episodes of febrile neutropenia and documented infections after dose-intensive treatment with VDC and IE.
RCT Entities:
PURPOSE: To compare the effectiveness, tolerance, and pharmacokinetics of a single dose of pegfilgrastim to daily filgrastim in children and young adults with sarcomas treated with dose-intensive combination chemotherapy. EXPERIMENTAL DESIGN:Patients were randomized to receive a single dose of 100 mcg/kg of pegfilgrastim s.c. or 5 mcg/kg/day of filgrastim s.c., daily until neutrophil recovery after two treatment cycles with vincristine, doxorubicin, and cyclophosphamide (VDC) and two cycles of etoposide and ifosfamide (IE). The duration of severe neutropenia (absolute neutrophil count, < or =500/mcL) during cycles 1 to 4 and cycle duration for all cycles were compared. Pharmacokinetics of pegfilgrastim and filgrastim and CD34+ stem cell mobilization were studied on cycle 1. Growth factor-related toxicity, transfusions, and episodes of fever and neutropenia and infections were collected for cycles 1 to 4. RESULTS: Thirty-four patients (median age, 20 years; range 3.8-25.8) were enrolled, and 32 completed cycles 1 to 4. The median (range) duration of absolute neutrophil count of <500/mcL was 5.5 (3-8) days for pegfilgrastim and 6 (0-9) days for filgrastim (P = 0.76) after VDC, and 1.5 (0-4) days for pegfilgrastim and 3.75 (0-6.5) days for filgrastim (P = 0.11) after IE. More episodes of febrile neutropenia and documented infections occurred on the filgrastim arm. Serum pegfilgrastim concentrations were highly variable. Pegfilgrastim apparent clearance (11 mL/h/kg) was similar to that reported in adults. CONCLUSION: A single dose per cycle of pegfilgrastim was well tolerated and may be as effective as daily filgrastim based on the duration of severe neutropenia and number of episodes of febrile neutropenia and documented infections after dose-intensive treatment with VDC and IE.
Authors: Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff Journal: J Clin Oncol Date: 2006-05-08 Impact factor: 44.544
Authors: F A Holmes; J A O'Shaughnessy; S Vukelja; S E Jones; J Shogan; M Savin; J Glaspy; M Moore; L Meza; I Wiznitzer; T A Neumann; L R Hill; B C Liang Journal: J Clin Oncol Date: 2002-02-01 Impact factor: 44.544
Authors: Esther M te Poele; Willem A Kamps; Rienk Y J Tamminga; Jan A Leeuw; Aleida Postma; Evelina S J M de Bont Journal: J Pediatr Hematol Oncol Date: 2005-11 Impact factor: 1.289
Authors: E Johnston; J Crawford; S Blackwell; T Bjurstrom; P Lockbaum; L Roskos; B B Yang; S Gardner; M A Miller-Messana; D Shoemaker; J Garst; G Schwab Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: Nicolas André; Maria El Kababri; Pourroy Bertrand; Angelique Rome; Carole Coze; Jean Claude Gentet; Jean Louis Bernard Journal: Anticancer Drugs Date: 2007-03 Impact factor: 2.248
Authors: K H Park; J H Sohn; S Lee; J H Park; S Y Kang; H Y Kim; I H Park; Y H Park; Y H Im; H J Lee; D S Hong; S Park; S H Shin; H C Kwon; J H Seo Journal: Invest New Drugs Date: 2013-05-16 Impact factor: 3.850
Authors: Wen-Yu Yang; Tian-Feng Liu; Xiao-Juan Chen; Ye Guo; Ting Li; Ben-Quan Qi; Fang Liu; Li-Xian Chang; Min Ruan; Xiao-Ming Liu; Li Zhang; Yao Zou; Yu-Mei Chen; Xiao-Fan Zhu Journal: Zhongguo Dang Dai Er Ke Za Zhi Date: 2020-11
Authors: Margarita B Belogurova; Zoryana P Kizyma; Miklós Garami; Mónika Csóka; Michael J Lamson; Anton Buchner; Peter Bias; Andreas Lammerich Journal: Cancer Chemother Pharmacol Date: 2016-12-16 Impact factor: 3.333
Authors: Tao Xie; Hui Fang; Weiming Ouyang; Phillip Angart; Meng-Jung Chiang; Ashwinkumar A Bhirde; Faruk Sheikh; Patrick Lynch; Ankit B Shah; Sharadrao M Patil; Kang Chen; Meiyu Shen; Cyrus Agarabi; Raymond P Donnelly; Kurt Brorson; Sarah J Schrieber; Kristina E Howard; Sarah M Rogstad; David M Frucht Journal: Sci Rep Date: 2020-02-12 Impact factor: 4.379